What is the 13F Pro Quality Score for ADMA?

13F Pro ranks ADMA BIOLOGICS, INC. (ADMA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ADMA's current score at https://13fpro.ai/company/ADMA (free sign-up required for the full ranking).

Which hedge funds own the most ADMA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ADMA include BlackRock,, STATE STREET, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ADMA as soon as new 13F filings post.

Where does 13F Pro source ADMA data?

All ADMA BIOLOGICS, INC. fundamentals and ownership data come directly from SEC EDGAR. ADMA BIOLOGICS, INC. files with the SEC under CIK 1368514. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ADMA in?

ADMA BIOLOGICS, INC. (ADMA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives ADMA's revenue?

Per ADMA BIOLOGICS, INC.'s latest 10-Q filed with the SEC on 2026-08-05, the biggest revenue drivers are: ADMA BioManufacturing ($123.6M, +1.4% YoY); ASCENIV ($102.9M, +23.5% YoY); BIVIGAM ($19.4M, -48.5% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/ADMA.

What are ADMA's largest expenses?

ADMA BIOLOGICS, INC.'s latest 10-Q reports these as the largest expense items: Selling, general and administrative ($26.7M, +20.4% YoY); Research and development ($6.0M, +383% YoY); Plasma center operating expenses ($1.0M, -10.9% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is ADMA research updated on 13F Pro?

ADMA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ADMA BIOLOGICS, INC.(ADMA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1368514 ADMA stock profile & AI dashboard →

13F Pro Quality Score

69.7/100

Rank #249 of 2,961 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

86.0/100

Profitability

86.8/100

Balance Sheet

98.0/100

Earnings Quality

59.3/100

Free Cash Flow

76.2/100

Institutional Flow

12.8/100

Revenue Scale

37.8/100

Dilution Risk

28.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why ADMA Scores 70/100

exact factor attribution · 2026-09-11

ADMA's composite is driven by revenue growth and profitability, held back by institutional flow and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+7.2 pts

86th pct

Profitability

+5.5 pts

87th pct

Capital efficiency

+4.8 pts

98th pct

Free cash flow

+3.9 pts

76th pct

Earnings growth

+2.2 pts

93th pct

Earnings quality

+0.9 pts

59th pct

Shareholder dilution

-1.1 pts

28th pct

Scale

-1.8 pts

38th pct

Institutional flow

-1.9 pts

13th pct

Latest change (2026-08-07): 76 → 71 · ↓ Revenue growth 89→70; despite ↑ Free cash flow 64→76

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

ADMA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for ADMA BIOLOGICS, INC. (ADMA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ADMA at 69.7/100 on a 32-signal composite quality model, placing it at rank #249 of 2,961 stocks — the top 10% of the AI-ranked universe. ADMA scores in the top quartile across balance sheet strength (98.0), profitability (86.8), revenue growth (86.0). Areas of concern include institutional flow (12.8) and revenue scale (37.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ADMA BIOLOGICS, INC. reports quarterly revenue of $124.4M, net income of $37.8M, an operating margin of 42.2%. Top institutional holders of ADMA by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. ADMA trades on the Nasdaq exchange and files with the SEC under CIK 1368514. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADMA BIOLOGICS, INC. directly from SEC EDGAR. ADMA BIOLOGICS, INC.'s 13F Pro composite quality score has ranged between 24 and 77 since 2021, currently 69.7 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about ADMA BIOLOGICS, INC.

Quirks, history, and lore behind ADMA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · focused on plasma-derived therapeutics · listed on Nasdaq · headquartered in Florida.
2
The Numbers
A small-cap name with annual revenues in the hundreds of millions of dollars — tiny by pharma standards, but growing fast as demand for its products climbs.
3
The History
Founded in the early 2000s, it spent years building out its own plasma collection and manufacturing infrastructure rather than relying on third parties — a capital-heavy bet that took a long time to pay off.
4
The Secret
Its core products treat patients with primary immune deficiencies and other conditions that leave the immune system dangerously under-armed — think intravenous immunoglobulin (IVIG).
5
The Lore
The company owns and operates its own FDA-licensed plasma collection centers and a dedicated manufacturing facility in Boca Raton — a vertically integrated model rare among small biotechs.
6
The Giveaway
Its flagship product BIVIGAM and its portfolio of plasma-derived biologics come from a company whose very name fuses "ADMA" with the business of keeping immune-compromised patients alive.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving ADMA's Business? Latest 10-Q Breakdown

AI-extracted from ADMA BIOLOGICS, INC.'s 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

ADMA's Q2 revenue grew just 2.0% to $124.4M as 23.5% ASCENIV growth was nearly offset by a 48.5% BIVIGAM decline from competitive IVIG pricing pressure, while gross margin expanded sharply to 69.4% from 55.1%.

Biggest Revenue Drivers

ADMA BioManufacturing$123.6M+1.4% YoY

Plasma Collection Centers$0.7M+100.0% YoY

Biggest Revenue Drivers

Total revenue: $124.4M+2.0% YoY

ADMA BioManufacturing$123.6M+1.4% YoY

Within ADMA BioManufacturing

ASCENIV$102.9M+23.5% YoY

Reflects continued growth in market acceptance of the product

BIVIGAM$19.4M-48.5% YoY

Reflects continued competitive pressures in the standard immune globulin market

Plasma Collection Centers$0.7M+100.0% YoY

Largest Expense Items

Selling, general and administrative$26.7M+20.4% YoY

Higher employee-related costs, increased software maintenance costs, and higher professional and legal fees tied to ongoing litigation and strategic initiatives

Research and development$6.0M+383% YoY

Ramp-up of clinical development and trial activities related to the SG-001 development project

Plasma center operating expenses$1.0M-10.9% YoY

Decrease primarily due to the sale of three plasma centers in the first quarter of 2026

Margins: Gross margin rose to 69.4% from 55.1% a year ago, driven by favorable product mix (higher ASCENIV, lower BIVIGAM) and margin benefits from the FDA-approved yield enhancement manufacturing process.

Watch Items from the Filing

Three customers represented approximately 76% of Q2 2026 consolidated revenues; two customers (BioCare and CuraScript) represented approximately 81% of accounts receivable at quarter-end.
On July 10, 2026 a putative securities class action (Mazzarino v. ADMA) was filed against the company and certain officers alleging Exchange Act violations; damages unspecified and no accrual recorded.
New FDA-approved IVIG products entering the market with aggressive pricing tactics (extended payment terms, rebates, discounts) drove the 48.5% BIVIGAM revenue decline and elevated industry-wide inventory.
Company borrowed $125.0M under its JPM Revolving Facility to fund an accelerated share repurchase, leaving $198.1M in variable-rate debt outstanding as of June 30, 2026.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$124.4M

Net Income

Q2 2026

$37.8M

Free Cash Flow

Q2 2026

$27.3M

Operating Margin

Q2 2026

42.2%

ROIC

Q2 2026

34.5%

D/E Ratio

Q2 2026

0.49

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+19.6% YoY

$510.2MFY 2025

FY22 $154.1MFY23 $258.2MFY24 $426.5MFY25 $510.2M

Net Income

-25.7% YoY

$146.9MFY 2025

FY22 $-65.9MFY23 $-28.2MFY24 $197.7MFY25 $146.9M

Operating Income

+37.7% YoY

$191.4MFY 2025

FY22 $-39.4MFY23 $21.6MFY24 $139.0MFY25 $191.4M

EPS (Diluted)

-25.9% YoY

$0.60FY 2025

FY22 $-0.33FY23 $-0.13FY24 $0.81FY25 $0.60

Total Assets

+27.7% YoY

$624.2MFY 2025

FY22 $348.5MFY23 $329.2MFY24 $488.7MFY25 $624.2M

Total Debt

+3.6% YoY

$75.0MFY 2025

FY22 —FY23 —FY24 $72.3MFY25 $75.0M

Op. Cash Flow

-57.5% YoY

$50.4MFY 2025

FY22 $-59.5MFY23 $8.8MFY24 $118.7MFY25 $50.4M

Free Cash Flow

-74.8% YoY

$27.8MFY 2025

FY22 $-73.4MFY23 $4.0MFY24 $110.4MFY25 $27.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$510.2M +19.6%	$426.5M +65.2%	$258.2M +67.6%	$154.1M +90.4%	$80.9M +91.7%	$42.2M
Net Income	$146.9M -25.7%	$197.7M +800.0%	$-28.2M +57.2%	$-65.9M +8.0%	$-71.6M +5.4%	$-75.7M
Operating Income	$191.4M +37.7%	$139.0M +542.5%	$21.6M +155.0%	$-39.4M +32.6%	$-58.4M +10.1%	$-64.9M
EPS (Diluted)	$0.60 -25.9%	$0.81 +723.1%	$-0.13 +60.6%	$-0.33 +35.3%	$-0.51 +42.0%	$-0.88
Total Assets	$624.2M +27.7%	$488.7M +48.5%	$329.2M -5.5%	$348.5M +26.1%	$276.3M +33.0%	$207.7M
Total Debt	$75.0M +3.6%	$72.3M	—	—	—	—
Operating Cash Flow	$50.4M -57.5%	$118.7M +1248.5%	$8.8M +114.8%	$-59.5M +47.0%	$-112.4M -10.2%	$-102.0M
Free Cash Flow	$27.8M -74.8%	$110.4M +2641.3%	$4.0M +105.5%	$-73.4M +41.7%	$-125.9M -9.7%	$-114.7M

Get alerted when ADMA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ADMA BIOLOGICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ADMA

BlackRock, Inc.
$321.0M38,355,684 sh
STATE STREET CORP
$143.3M17,116,022 sh
VANGUARD CAPITAL MANAGEMENT LLC
$84.6M10,103,809 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$84.4M10,088,490 sh
Rubric Capital Management LP
$78.2M9,339,414 sh
Capital Research Global Investors
$73.3M8,756,374 sh
FIRST TRUST ADVISORS LP
$65.3M7,798,351 sh
GEODE CAPITAL MANAGEMENT, LLC
$50.7M6,059,984 sh
Caligan Partners LP
$47.9M5,725,007 sh
D. E. Shaw & Co., Inc.
$44.1M5,274,597 sh

Fund	Value	Shares
BlackRock, Inc.	$321.0M	38,355,684
STATE STREET CORP	$143.3M	17,116,022
VANGUARD CAPITAL MANAGEMENT LLC	$84.6M	10,103,809
VANGUARD PORTFOLIO MANAGEMENT LLC	$84.4M	10,088,490
Rubric Capital Management LP	$78.2M	9,339,414
Capital Research Global Investors	$73.3M	8,756,374
FIRST TRUST ADVISORS LP	$65.3M	7,798,351
GEODE CAPITAL MANAGEMENT, LLC	$50.7M	6,059,984
Caligan Partners LP	$47.9M	5,725,007
D. E. Shaw & Co., Inc.	$44.1M	5,274,597

Companies Similar to ADMA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

HRMY

Harmony Biosciences Holdings, Inc.

AI score

Similar quality profile · 16 shared holders

Bridgewater Associates, LP Virtus Investment Advisers, LLC DIADEMA PARTNERS LP

MGTX

MeiraGTx Holdings plc

AI score

Similar quality profile · 13 shared holders

Rubric Capital Management LP KENNEDY CAPITAL MANAGEMENT LLC PERCEPTIVE ADVISORS LLC

HALO

HALOZYME THERAPEUTICS, INC.

AI score

Similar quality profile · 7 shared holders

KENNEDY CAPITAL MANAGEMENT LLC JUPITER ASSET MANAGEMENT LTD Bridgewater Associates, LP

ANIP

ANI PHARMACEUTICALS INC

AI score

Similar quality profile · 15 shared holders

Rubric Capital Management LP Ranger Investment Management, L.P.KENNEDY CAPITAL MANAGEMENT LLC

PBH

Prestige Consumer Healthcare Inc.

AI score

Similar quality profile · 17 shared holders

Bridgewater Associates, LP Freestone Grove Partners LP SummitTX Capital, L.P.

BLFS

BIOLIFE SOLUTIONS INC

AI score

Similar quality profile · 8 shared holders

Ranger Investment Management, L.P.CenterBook Partners LP FOX RUN MANAGEMENT, L.L.C.

ALNY

ALNYLAM PHARMACEUTICALS, INC.

AI score

Similar quality profile · 6 shared holders

Capital Research Global Investors Life Cycle Investment Partners Ltd Bridgewater Associates, LP

ZVRA

ZEVRA THERAPEUTICS, INC.

AI score

Similar quality profile · 7 shared holders

Nantahala Capital Management, LLC Stonepine Capital Management, LLC CAXTON ASSOCIATES LLP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ADMA on your watchlist

Track score changes the day ADMA BIOLOGICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ADMA a good stock to buy?

13F Pro's AI-powered analysis of ADMA BIOLOGICS, INC. (ADMA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADMA are available on the ADMA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ADMA is classified as a mid company.

Which hedge funds own ADMA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADMA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADMA BIOLOGICS, INC.'s investment landscape.